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A B S T R A C T
Triphasic waves are seen in the electro-encephalogram of adult patients with toxic-metabolic
encephalopathies of various origins. Levetiracetam is a broad spectrum anti-epileptic drug with renal
elimination and no hepatic metabolism. We describe the case of encephalopathy with triphasic waves
concomitant with levetiracetam accumulation in a patient with chronic renal failure. The condition was
reversible after down-titration of levetiracetam with no change of the renal function. Other causes of
metabolic encephalopathy were excluded. Moreover, this patient suffered from a probable cortical
myoclonus that relapsed after cessation of the drug butwaswell controlled by a lowdosage adapted to the
renal failure. In cases of metabolic encephalopathy with triphasic waves in a patient with renal failure
taking levetiracetam, it is important to exclude toxic accumulation of levetiracetam among other causes.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Multifocal or diffuse triphasic waves are electro-encephalo-
graphic (EEG) patterns seen in toxic-metabolic encephalopathies
in adults. Previously thought to be speciﬁc to hepatic encephalo-
pathy,1 they have been described in a variety of other etiologies
such as hyper-azotemia, hypoxia, thyroid disease, hyperammo-
nemia caused by valproic acid, cefepime intoxication in patients
with chronic renal failure and various other drug-related condi-
tions including lithium, naproxen, levodopa, as well as in a variety
of non-metabolic causes.2–6
Levetiracetam is a new anti-epileptic drug with renal elimina-
tion and no hepatic metabolism which is widely homologated for
partial onset or primary generalized seizures, as well as epileptic
and non-epileptic myoclonic conditions.6,7 Reversible dose-
dependent side effects include sedation and dizziness. We report
the ﬁrst case of metabolic encephalopathy with triphasic waves
associated with levetiracetam intoxication in a patient with
cortical myoclonus of vascular origin.
2. Case report
In March 2007, an 80-year-old woman was admitted to our
hospital for repetitive generalized myoclonic jerks, also involving
the diaphragma, together with a moderate confusional state.* Corresponding author. Tel.: +41 22 372 83 52; fax: +41 22 372 83 40.
E-mail address: serge.vulliemoz@hcuge.ch (S. Vulliemoz).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.01.006Another similar episode had already occurred in 2001, culminating
in a secondary generalized tonic-clonic seizure. She had been
discharged on valproic acid with the diagnosis of post-stroke
symptomatic seizures. The treatment of valproic acid was stopped
a year later, in 2002, because of drug-induced hyperammonemic
encephalopathy and was replaced with levetiracetam (2
1000 mg/day). Her medical history included hypertension, non-
insulin-dependant diabetes mellitus and chronic renal failure,
together with a discrete vascular parkinsonism in the context of a
widespread vascular leuco-encephalopathy. The rest of the
treatment consisted in verapamil, propranolol, metformine,
oxazepam, escitalopram and levodopa/benserazide (3 100/
25 mg/day) with no recent treatment change. Neurological
examination showed resting and action myoclonus of the four
extremities together with vocalization induced by synchronous
diaphragmaticmyoclonus. Therewas amoderate confusional state
but no other relevant neurological feature on examination. The
myoclonus stopped spontaneously a few days after admission.
Blood tests showed a normal count of blood cells, normal
electrolytes (natrium, kalium, calcium, magnesium), increased
creatinin level (148mmol/l norm 35–88, clearance: 29 ml/min,
norm corrected for age: 40–75 ml/min), normal liver enzymes,
normal serum ammonium, normal thyroid function and absent
anti-thyroid antibodies. A lumbar puncture showed no abnorm-
ality in the cerebro-spinal ﬂuid. The MRI showed a severe vascular
leuco-encephalopathy together with a right prefrontal cortical
vascular lesion. The EEG after the cessation of the myoclonus
showed a background slowing with no epileptiform activity.
Neuropsychological examination revealed executive and memoryvier Ltd. All rights reserved.
Fig. 1. EEG (all panels with Low Pass ﬁlter 70 Hz, High Pass 0.3 Hz, Notch 50 Hz, 20 s/page): (a) diffuse slowing with multifocal triphasic waves (arrows) associated with
levetiracetam accumulation; (b) normalization of the EEG after down titration of levetiracetam according to the renal function; (c) relapse of myoclonic jerks 48 h after total
cessation of levetiracetam. Epileptogenic focus with spikes and polyspikes at the vertex occurring with/without or without synchronous myoclonic jerks (thick/thin arrow);
(d) same EEG page as (c), displayed in a transverse montage to highlight the paramedian localisation of the epileptiform discharges.
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discharged with no treatment change.
Two months later, she was readmitted for a relapse of very
frequent myoclonic jerks occuring in a status myoclonicus
presentation, again combined with a moderate confusional state.
EEG showed a diffuse theta-delta slowing with prominent multi-
focal triphasic waves (Fig. 1a). Generalized myoclonic jerks
involving the diaphragma occurred during the recording with no
paroxysmal EEG correlate.
Standard laboratory tests showed a stable renal insufﬁciency.
Since the patient was taking 2 1000 mg/day of levetiracetam in
the context of renal failure, accumulation and intoxication was
suspected and the drug lowered to 2 250 mg/day. Three days
later, the myoclonic jerks had disappeared, the cognitive
functions were back to baseline and the EEG showed normal
background activity (Fig. 1b). Retrospective plasma level of
levetiracetam8 on the serum isolated on the admission day
showed elevated values (184 mmol/l, compared to values
commonly observed in patients stabilized on therapeutic
levetiracetam doses: ‘‘therapeutic range’’ = 35–120 mmol/l9),
while the drug level after down titration was within therapeutic
range (53 mmol/l). Levetiracetam was then completely stopped.
Two days later, there was a renewed intense relapse of myoclonic
jerks with no worsening of the renal function, infection or
electrolyte imbalance. During repetition of the EEG,multiple jerks
were recorded. An epileptic focus with spikes and polyspikes
located over the frontalmidline was observed, suggesting cortical
origin of the myocloni (Fig. 1c and d). Levetiracetam was
reintroduced at the dose of 2 250 mg/day. For a more rapid
relief of the patient, small doses of clonazepam (2 0.25 mg/day)
were added for 3 days, then halved for 1 day and ﬁnally stopped.The myoclonus did not relapse after cessation of clonazepam and
the last plasma level of levetiracetam at discharge was within
therapeutic range (90 mmol/l). Somatosensory evoked potentials,
performed during low-dose levetiracetam therapy in the absence
ofmyoclonus, did not reveal giant potentials. Follow-up 6months
after hospital discharge revealed a stable condition with no
relapse of myoclonus.
3. Discussion
To the best of our knowledge, this is the ﬁrst report ofmetabolic
encephalopathy with triphasic waves so closely associated with
intoxication with levetiracetam in the context of chronic renal
failure.
The improvement in the clinical condition and the EEG after
reduction of this drug as well as concomitant normalization of the
elevated drug plasma level are strong arguments supporting this
etiology. The stability of the renal function despite dramatic
clinical and EEG changes does not suggest a direct participation of
this condition in the clinical picture, except by causing the
accumulation of the involved drug. No other treatment change
could explain this rapid evolution highly suggestive of a toxic-
metabolic origin. The patient was also taking levodopa reported to
cause metabolic encephalopathy in the context of dose increase
and for higher baseline doses.10 Since this drug has a hepatic
metabolism and was only given in small dosage in a patient with
no hepatic dysfunction, its role in the encephalopathy is unlikely.
Moreover, no other signs of levodopa overdose, such as choreo-
athetotic dyskinesia, were observed. Although they can be toxic to
the CNS, the other concomitant drugs have not been reported to be
related to encephalopathy with triphasic waves. Among other
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sign of thyroid disease.
Interestingly, levetiracetam has been shown to undergo a
signiﬁcant in vivo metabolism when serum was not quickly
separated from the whole blood11 and this has to be considered
when assessing the level of this drug, especially if this is done
retrospectively. In our hospital, serum was separated from whole
blood following the usual practice of the local chemistry laboratory
within a few hours. According to the study by Patsalos et al., in situ
metabolism of levetiracetam can only affect measured levels of the
drug if whole blood is conserved and the serum not stored
separately. Therefore, in our laboratory setting, in situ metabolism
of levetiracetam would not have exceeded a few percent of the
total blood level in the worst scenario and could not explain the 3-
fold difference of serum drug levels obtained in consecutive
measurements.
Levetiracetam has reported anti-myoclonic effect acting on
cortical, and subcortical as well as spinal myoclonus.6,12–14 The
spikes recorded on the EEG after complete cessation of levetir-
acetam strongly suggest a cortical origin of the myoclonus,
probably secondary to a vascular lesion in the context of a diffuse
vascular encephalopathy. The absence of giant evoked potentials,
tested under levetiracetam treatment, does not exclude the
cortical origin suggested by the EEG, since giant evoked potentials
reportedly become normal after institution of anti-myoclonic
treatment and can even be absent in untreated patients with
cortical myoclonus.14 In this particular case, levetiracetam seems
to have a bell-shaped effect on the generalized myoclonus: at
therapeutic doses adapted to the renal function, the drug
suppressed the jerks, while, at supra-therapeutic dosage, it
induced a toxic encephalopathy that lowered the threshold for
the myoclonus and caused it to recur.
This case adds evidence to the potent anti-myoclonic effect of
levetiracetam at therapeutic doses. Triphasic waves on the EEG in a
patient with renal failure taking levetiracetam should not only
suggest the possibility of renal/uremic encephalopathy but also
raise the concern of possible toxic accumulation of levetiracetam
as a signiﬁcant contributor to the toxic-metabolic encephalopathy.
In clinical practice, a single deﬁnite trigger of the encephalopathy is
often hard to isolate in elderly patients with multiple co-
morbidities and multiple drug treatments. Therefore, even if
levetiracetammight have acted as a concomitant factor rather than
as the single trigger, the consequences for the clinical managementremain the same and aim at reducing concomitant aggravating/
triggering metabolic and toxic factors. This is of clinical relevance
since an increasing number of elderly patients with multiple co-
morbidities are treated with levetiracetam and these patients are
precisely those at risk for toxic/metabolic encephalopathy because
of their medical condition and multiple drug treatments.
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